Next report date
Report period
Q1 2024
EPS estimate
−1.18USD
Revenue estimate
3.41 MUSD
−10.41USD
−13.58 MUSD
13.80 MUSD
2.53 M
About Vivos Therapeutics, Inc.
Sector
Industry
CEO
R. Kirk Huntsman
Website
Headquarters
Littleton
Employees (FY)
114
Founded
2016
FIGI
BBG00H1NZV76
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.
VVOS BreakoutDaily Trend Reversal, seems like it's in a loading zone, I like the volume profile gap to the 5.00. Low Float. Need to stay above 2.40 +
Nice PatternVVOS is an interesting little company. They seem to have a much better approach to the Sleep Apnea issue.
The chart is at an interesting point.
Wild Bull post market move watch.I want to track what happens to ANY and VVOS who both just had 30-50% moves post market.
Will the trend then continue - or cool off?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VVOS is 2.56 USD — it has decreased by 0.45% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vivos Therapeutics, Inc. stocks are traded under the ticker VVOS.
Vivos Therapeutics, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
VVOS stock is 9.70% volatile and has beta coefficient of 2.12. Check out the list of the most volatile stocks — is Vivos Therapeutics, Inc. there?
VVOS earnings for the last quarter are −1.75 USD per share, whereas the estimation was −3.00 USD resulting in a 41.67% surprise. The estimated earnings for the next quarter are −1.91 USD per share. See more details about Vivos Therapeutics, Inc. earnings.
Vivos Therapeutics, Inc. revenue for the last quarter amounts to 3.30 M USD despite the estimated figure of 4.50 M USD. In the next quarter revenue is expected to reach 3.41 M USD.
Yes, you can track Vivos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
VVOS stock has fallen by 8.30% compared to the previous week, the month change is a 44.50% fall, over the last year Vivos Therapeutics, Inc. has showed a 71.90% decrease.
VVOS net income for the last quarter is −4.26 M USD, while the quarter before that showed −2.09 M USD of net income which accounts for −103.49% change. Track more Vivos Therapeutics, Inc. financial stats to get the full picture.
Today Vivos Therapeutics, Inc. has the market capitalization of 7.02 M, it has decreased by 2.22% over the last week.
No, VVOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VVOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vivos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 114.00 employees. See our rating of the largest employees — is Vivos Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vivos Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vivos Therapeutics, Inc. stock shows the strong sell signal. See more of Vivos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Vivos Therapeutics, Inc. future price: according to them, VVOS price has a max estimate of 8.25 USD and a min estimate of 6.20 USD. Read a more detailed Vivos Therapeutics, Inc. forecast: see what analysts think of Vivos Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vivos Therapeutics, Inc. EBITDA is −16.67 M USD, and current EBITDA margin is −120.82%. See more stats in Vivos Therapeutics, Inc. financial statements.